Hunter Diamond

Ahu Demir

Aydin Huseynov

Mike King

- **Salarius Pharmaceuticals, Inc. (SLRX) regained compliance with all Nasdaq listing requirements** as of October 10, 2025, specifically the Equity Standard Requirement.  **[1615219_0001615219-25-000145_a101325slrxregainsnasdaqco.htm:0]** **[1615219_0001615219-25-000145_flks-20251010.htm:1]** 
- This follows the company's regaining compliance with the Minimum Bid Price Requirement on September 9, 2025.  **[1615219_0001615219-25-000145_a101325slrxregainsnasdaqco.htm:0]** 
- The company will be subject to a **Mandatory Panel Monitor for one year** from October 10, 2025.  **[1615219_0001615219-25-000145_a101325slrxregainsnasdaqco.htm:0]** **[1615219_0001615219-25-000145_flks-20251010.htm:1]** 
- Regaining compliance is a **critical step in its planned merger with Decoy Therapeutics**, which was announced on January 13, 2025.  **[1615219_0001615219-25-000145_a101325slrxregainsnasdaqco.htm:0]**

Salarius Pharmaceuticals Regains Nasdaq Compliance

- Salarius Pharmaceuticals, Inc. entered into a **Fifth Amendment to its Agreement and Plan of Merger** on **September 17, 2025**, with Decoy Therapeutics Inc. and its subsidiaries.  **[1615219_0001615219-25-000135_projectsierra-fifthamendme.htm:0]** **[1615219_0001615219-25-000135_flks-20250917.htm:1]** 
- The amendment modifies the conversion terms for Series A and Series B Non-Voting Convertible Preferred Stock, establishing an **Initial Issuance Price of $10.50 per share** as the baseline for conversion ratio adjustments in dilutive subsequent financings.  **[1615219_0001615219-25-000135_flks-20250917.htm:1]** 
- A **floor price of $3.75 per share** has been set for the price protection calculation triggered by a Subsequent Financing.  **[1615219_0001615219-25-000135_flks-20250917.htm:1]** 
- The **redemption price per share of Series B Preferred Stock** was changed to the Initial Issuance Price multiplied by 1,000.  **[1615219_0001615219-25-000135_flks-20250917.htm:1]** **[1615219_0001615219-25-000135_certificateofdesignations-.htm:15]**

Salarius Pharmaceuticals (SLRX)